Buprenorphine Base

Overview: Buprenorphine Base is a potent medication designed for effective pain management and the treatment of opioid use disorder. As a semisynthetic opioid, it provides significant analgesic effects while minimizing the risks associated with traditional full agonist opioids.

Key Features of Buprenorphine Base:

• Potency: Buprenorphine Base is 25 to 50 times more potent than morphine, making it an effective option for patients requiring strong pain relief.
• Pharmacological Properties: As a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, it offers effective pain relief while reducing the risk of respiratory depression and overdose.
• Long Duration of Action: This API has a prolonged duration of action, providing relief from pain or withdrawal symptoms for up to 24-36 hours, which allows for convenient once-daily dosing.

Benefits of Buprenorphine Base:

• Lower Abuse Potential: Due to its partial agonist properties, Buprenorphine Base has a lower potential for misuse compared to full agonist opioids, making it a safer choice for patients with a history of substance use disorders.
• Reduced Withdrawal Symptoms: This medication effectively alleviates withdrawal symptoms and cravings in individuals undergoing treatment for opioid use disorder.
• Improved Safety Profile: This API’s ceiling effect limits the potential for overdose, enhancing patient safety during treatment.

Buprenorphine is available in several formulations, including:

• Buprenorphine API: This formulation is used in various delivery methods, including tablets and implants:
  • Buprenorphine Base
  • Buprenorphine Hydrochloride
• Buprenorphine Sublingual: Buprenorphine Tablets allow for rapid onset of action as the medication dissolves under the tongue:
  • Buprenorphine Sublingual 0.4 mg
  • Buprenorphine Sublingual 2 mg
  • Buprenorphine Sublingual 8 mg
• Intermediates:
  • N-Methylnorbuprenorphine 3-methyl ether
  • (5R,6R,7S,9R,13S,14S,20S)-17-Cyclopropylmethyl-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3,6-dimethoxy-α-methyl-6,14-ethanomorphinan-7-methanol

Indications of Buprenorphine Base:

• Management of severe acute and chronic pain where other treatments are inadequate.
• Treatment of opioid use disorder as part of a comprehensive recovery program that includes counseling and behavioral therapy.

Dosage and Administration:

It can be administered via various routes, including sublingual tablets and transdermal patches. The sublingual tablets should be placed under the tongue until fully dissolved.

Contraindications:

• Hypersensitivity to buprenorphine or any components of the formulation.
• Significant respiratory depression or acute asthma in an unmonitored setting.

Warnings and Precautions:

• Cardiovascular disease
• Hepatic impairment
• History of seizures or respiratory issues

Side Effects:

Common side effects may include:

• Nausea
• Constipation
• Dizziness
• Headache

Manufacturer: Pluvia Endo manufactures Buprenorphine Base, ensuring high-quality standards and compliance with regulatory requirements.

For more information from Pluvia Endo or to place an order, don’t hesitate to contact us today!